经皮影像引导冷冻消融治疗腹壁子宫内膜异位症的可行性与安全性
该回顾性研究纳入18例腹壁子宫内膜异位症患者,共行18次CT或MR引导下经皮冷冻消融,治疗23个病灶。技术成功率100%,无SIR重大并发症;影像随访的16个病灶中15个(94%)无残余强化或T1高信号,临床随访14例中13例(93%)症状改善。结论认为该技术可行且安全性良好,但需进一步纵向研究验证持久疗效。
要点
- CT或MR引导下经皮冷冻消融治疗腹壁子宫内膜异位症技术成功率达100%,无SIR重大并发症。
- 影像随访中94%(15/16)病灶无残余强化或T1高信号,提示局部控制良好。
关键影像表现/征象
- 影像随访(中位85天)的16个病灶中,15个(94%)治疗部位无残余强化或T1高信号。
- 1个病灶(6%)影像随访显示残余或进展性疾病。
- 13/18例(72%)术中使用水分离技术推移邻近肠管、膀胱或神经血管结构。
诊断标准与关键数值
- 技术成功定义为18/18例(100%)完成冷冻消融操作。
- 影像随访成功标准为治疗部位无残余强化或T1高信号,16个随访病灶中15个(94%)达到。
- 临床随访14例中13例(93%)报告腹壁子宫内膜异位症相关症状改善。
临床应用与阅片要点
- 术前应确认活检证实的腹壁子宫内膜异位症病灶(本组83%术前有活检证据)。
- 对于邻近肠管、膀胱或神经血管结构的病灶,可考虑使用水分离技术增加安全性(本组72%使用)。
- 术后影像随访关注治疗部位有无残余强化或T1高信号,以评估局部控制。
局限性
- 回顾性研究设计,样本量较小(18例患者)。
- 影像随访时间较短(中位85天),缺乏长期持久反应数据。
- 仅16/23个病灶(70%)获得影像随访,临床随访仅14例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the feasibility and safety of percutaneous image-guided cryoablation of abdominal wall endometriosis (AWE).
MATERIALS AND METHODS: A retrospective review of percutaneous cryoablation (CT or MR) of AWE was performed from January 2018 to December 2020. Eighteen patients were identified from an internal percutaneous ablation database. Technical success, complications, and outcomes were analyzed according to standard nomenclature.
RESULTS: Patients comprised 18 females (mean age 36.9 years) who underwent 18 cryoablation procedures to treat 23 AWE deposits. Three of the 18 cases were performed under MR guidance, while the remaining 15 employed CT guidance. Technical success was achieved in all 18 cases (100%). Fifteen of 18 patients (83%) had biopsy proven AWE deposits prior to treatment. Hydrodisplacement was used to displace adjacent bowel, bladder, or neurovascular structures in 13/18 cases (72%). The mean number of probes used per case was 3. Sixteen of 23 (70%) of AWE deposits had imaging follow-up (median 85 days). Of the 16 lesions with imaging follow-up, 15 (94%) demonstrated no residual enhancement or T1 hyperintensity at the treatment site and 1 lesion (6%) demonstrated residual/progressive disease. At clinical follow-up, 13 of 14 (93%) patients reported improvement in AWE-related symptoms. Eleven patients had clinically documented pain scores before and after ablation and all demonstrated substantial symptomatic improvement. No society of interventional radiology (SIR) major complications were observed.
CONCLUSIONS: Percutaneous cryoablation of AWE is feasible with a favorable safety profile. Further longitudinal studies are needed to document durable response over time.
引用
- Smith, Welch, Kurup, et al. Feasibility and safety of percutaneous image-guided cryoablation of abdominal wall endometriosis. Abdom Radiol (NY). 2021. PMID: 34773468. doi:10.1007/s00261-021-03344-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。